For healthcare professionals interested in additional scientific information and data regarding probiotics, this section provides a listing of:
Probiotic ArticlesThe following probiotic review articles and references provide additional information on available probiotics.
- Kligler B, Cohrssen A. Probiotics. Am Fam Physician 2008 Nov 1;78(9):1073-8.
- Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ. Recommendations for probiotic use—2011 update. J Clin Gastroenterol 2011 Nov;45 Suppl:S168-71.
- Douglas LC, Sanders ME. Probiotics and prebiotics in dietetics practice. J Am Diet Assoc 2008 Mar;108(3):510-21.
- World Gastroenterology Organisation Global Guidelines. Probiotics and Prebiotics. 2011 October. www.worldgastroenterology.org/probiotics-prebiotics.html.
- Brenner DM. Probiotics for the treatment of adult gastrointestinal disorders. www.patients.gi.org/topics/probiotics-for-the-treatment-of-adult-gastrointestinal-disorders/.
Bifidobacterium infantis 35624 Clinical Data Publications*If you are interested in additional scientific information and data regarding Bifidobacterium infantis 35624, below is a list of clinical publications.* A brief summary of additional clinical trials also is provided.
- Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006 Jul;101(7):1581-90.
- O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen KS, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EMM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005 Mar;128(3):541-51.
- Von Wright A, Vilpponen-Salmela T, Llopis MP, Collins K, Kiely B, Shanahan F, Dunne C. The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. International Dairy Journal. 2002;12:197-200.
- Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013 May-Jun;4(3):201-11.
Additional clinical data. A brief summary of an additional clinical trial that was presented at the 2011 American College of Gastroenterology Annual Scientific Meeting in Washington, DC is presented below.
Ringel Y, Ringel-Kulka T, McKean L, Ramsey D, Gibb R, McRorie J. Probiotic Bifidobacterium longum subsp. infantis 35624 in a non-patient population with a history of abdominal discomfort and bloating. Am J Gastroenterol. 2011 Oct;106(Suppl 2):S503. Abstract 1318.
A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of a probiotic (Bifidobacterium infantis 35624) in healthy subjects with a history of abdominal discomfort and bloating. Study Objective
To evaluate the benefit of B. infantis 35624 compared to placebo for abdominal discomfort and bloating in healthy subjects.
Study design: Multicenter, double-blind, randomized, parallel-group, placebo-controlled study consisting of 2 consecutive phases: a 2-week placebo run-in phase, followed by a 4-week treatment phase. Key inclusion criteria: Male or female subjects, 18 to 75 years of age, in general good health with BMI ≤ 40 who experienced abdominal discomfort and bloating at least twice a week, on average, over the last 3 months. Key exclusion criteria: Pregnant or nursing; abdominal discomfort and bloating predominantly related to menstruation; under a physician's care for functional bowel disorders (i.e., IBS, functional constipation, functional diarrhea, functional abdominal pain) or have taken prescription medication for functional bowel disorders within the past year; alarm symptoms suggestive of an underlying disease (weight loss, blood in stools, family history of colorectal cancer, relevant abnormalities on physical exam, acute onset of symptoms, subjects with diarrhea due to mal-absorptive disorders, abnormal lab test, positive stool cultures in subjects with prolonged diarrhea); prior gastrointestinal surgery; immunodeficiency. Outcome measures
Primary: Change from baseline in severity of each symptom (abdominal discomfort and bloating) at Week 4
Secondary: Change from baseline in severity of each symptom (abdominal discomfort and bloating) at Weeks 1, 2, and 3; subject reported global impression of change; time to no symptoms; proportion of days without symptoms
148 healthy non-patient subjects received 1 capsule/day of 1 x 109 CFU (colony-forming unit) B. infantis 35624. 154 healthy non-patient subjects received 1 capsule/day of placebo.
Subject demographics/disposition: B. infantis 35624 Placebo Sex: Female 79.7% 77.9% Age (mean): 42.2 41.4 Race: Caucasian 68.9% 77.9% Black 29.1% 20.1% Other 2.1% 1.8% Abdominal discomfort
(mean Week 2 run-in)
2.4 2.3 Abdominal bloating
(mean Week 2 run-in)
2.5 2.5 The active and placebo groups were balanced at baseline with respect to race, age, sex, ethnicity, smoking status, alcohol use, and caffeine use. A total of 10 subjects did not complete the study; 1 subject discontinued due to an adverse event. Efficacy results:
Primary: Both groups showed significant (p < 0.05) improvement versus baseline in abdominal discomfort and bloating scores over the 4-week intervention period. Mean severity symptom scores at Week 4 show no significant differences between the probiotic and placebo groups in either abdominal discomfort or bloating (p > 0.3).
- No significant differences between the probiotic and placebo groups were noted in severity of symptom scores at Weeks 1, 2, or 3 or in the subject-reported global impression of change.
- Subjects in the B. infantis 35624 group had significantly more bloating-free days compared with subjects in the placebo group (p < 0.05, 1-sided).
Adverse effects: Treatments were generally well tolerated. Both the B. infantis 35624 and placebo groups had an adverse event rate of 10%. The most commonly reported adverse events were gastrointestinal in nature. The majority of the adverse events was mild or moderate in severity and doubtfully related to study product. There was 1 serious adverse event of severe abdominal pain after 1 dose in a B. infantis 35624 subject. Conclusions: Both groups showed significant (p < 0.05) improvement in abdominal discomfort and bloating scores versus baseline over the 4-week intervention period. B. infantis 35624 did not show a significant improvement versus placebo in the mean severity of abdominal discomfort and bloating in a healthy, non-patient population. This may be explained by the high placebo effect and the lower severity, frequency, and impact of functional bowel symptoms in the non-patient population. Publication: Ringel Y, Ringel-Kulka T, McKean L, Ramsey D, Gibb R, McRorie J. Probiotic Bifidobacterium longum subsp. infantis 35624 in a non-patient population with a history of abdominal discomfort and bloating. Am J Gastroenterol. 2011 Oct;106(Suppl 2):S503. Abstract 1318.